C4 Therapeutics, Inc. (CCCC)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, C4 Therapeutics, Inc. reported revenue of $35.95M, up 1.0% from the prior year. The company ran a net loss, with a net margin of -292.1%. It held $359.07M in total assets against $102.49M in total liabilities.
Key ratios (FY2025)
-320.5%
Operating margin
-292.1%
Net margin
-40.9%
Return on equity
+1.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.95M | $35.58M | $20.76M | $31.10M | $45.78M | — | — | — |
| Operating Income | -$115.22M | -$119.61M | -$139.03M | -$129.53M | -$82.13M | -$60.45M | -$35.45M | — |
| Net Income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | -$83.89M | -$66.33M | -$34.10M | — |
| EPS (Diluted) | $-1.27 | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-5.83 | $-31.03 | — |
| Total Assets | $359.07M | $349.60M | $376.45M | $430.84M | $506.76M | $400.14M | $118.26M | — |
| Total Liabilities | $102.49M | $133.62M | $130.34M | $141.61M | $117.16M | $119.35M | $119.23M | — |
| Shareholders' Equity | $256.59M | $215.99M | $246.11M | $289.23M | $389.61M | $280.79M | -$111.96M | -$79.75M |
| Cash & Equivalents | $74.60M | $55.50M | $126.59M | $29.75M | $76.12M | $181.73M | $90.55M | — |
| Operating Cash Flow | -$98.69M | -$65.16M | -$106.84M | -$105.94M | -$86.97M | -$67.25M | $55.61M | — |
| Capital Expenditures | $607.0K | $180.0K | $1.71M | $5.50M | $1.28M | $650.0K | $1.35M | — |
| Shares Outstanding | 96.91M | 70.63M | 60.47M | 48.97M | 48.69M | 43.06M | 1.43M | — |